GNPX - Genprex Quarterly EPS earnings growth
Genprex, Inc. delegates production and testing to external partners, maintaining its status as a scientific hub. The quarterly EPS trend captures the impact of this model on capital, where 95.80 determines this parameter level. Diversification of research in oncology and diabetes mitigates risks, while innovative nanoparticles for lung cancer therapy create a barrier to entry for competitors.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_GNPX_-_Genprex-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "Genprex, Inc. (GNPX): Quarterly EPS earnings growth from 07/04/2022 to 11/14/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Genprex Inc (GNPX)
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
Debt to Equity Genprex, Inc.|GNPX - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Genprex, Inc.|GNPX - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Genprex, Inc|GNPX - Company Long-Term Loans and Borrowings|Company Short-Term Debts Genprex|Quick Liquidity Indicator genprex.com
- earnings and valuation multiples indicators:
GNPX - Company Profit|Future Profit Genprex, Inc.|GNPX - Company Value to Net Income|Forward P/E Multiple Genprex, Inc|GNPX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex, Inc|GNPX - Operating profit before amortization|Net earnings per share (EPS TTM) Genprex|GNPX - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months genprex.com|GNPX - Expected net earnings per share growth this year|Earnings growth forecast for next year Genprex, Inc.
- total revenue and sales volume data:
General company analysis:Genprex, Inc.
Genprex, Inc. specializes in developing innovative gene therapies for the treatment of lung cancer, focusing on long-term monetization through insurance reimbursements. Quarterly EPS variation allows for the mathematical monitoring of net income dynamics, eliminating subjectivity when assessing the rate of change in earnings per share, which is critical for minimizing the risk of capital freeze in low-liquidity biotech assets.
Who Genprex, Inc. competes with
BeiGene (ONC) - Year-over-year earnings per share growth for the last twelve months|Halozyme Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (RevMed) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Corp AAPG|Quarterly EPS earnings growth CGON|urogen.com (URGN) - Net earnings per share growth for the trailing year|Quarterly EPS earnings growth BCAX (Bicara Therapeutics)|Personalis Inc (PSNL) - Earnings per share growth in annualized terms for the last twelve months|ERAS - Year-over-year earnings per share growth for the last twelve months|DCTH (Delcath Corp) - Year-over-year earnings per share growth for the last 12 months|Y-mAbs Therapeutics (YMAB) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months AURA (aurabiosciences.com)|Year-over-year earnings per share growth for the last twelve months Candel Therapeutics Inc.|ARAY: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth SLS|ACTU - Earnings per share growth in annualized terms for the last twelve months|Citius Oncology, Inc. - Year-over-year net earnings per share growth for the last 12 months|HURA: Year-over-year earnings per share growth for the last 12 months|TARA: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FATE (Fate Therapeutics Inc)|WHWK: Quarterly EPS earnings growth|TCRX - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Champions Oncology Inc|Year-over-year earnings per share growth for the last 12 months XBIT (XBiotech USA)|Quarterly EPS earnings growth CVM|Year-over-year net earnings per share growth for the last 12 months OS Therapies Inc. OSTX|Radiopharm Theranostics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Artiva Biotherapeutics Inc. (ARTV)|Adlai Nortye Limited - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year verupharma.com (VERU)|Tempest Therapeutics, Inc. (TPST) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months XLO|Year-over-year earnings per share growth for the last twelve months Renovaro Biosciences|Mural Bio - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months KAPA (Kairos Pharma Ltd)|onkuretherapeutics.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth GDTC (CytoMed Therapeutics Limited)|CRIS - Year-over-year net earnings per share growth for the last 12 months|Apollomics Corp - Quarterly EPS earnings growth|THAR - Quarterly EPS earnings growth|advanbiomed.com (ADVB) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months CLDI|SBFM (Sunshine Biopharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Xenetic Bio (XBIO)|Quarterly EPS earnings growth SLRX|PPBT - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months American Oncology Network, Inc. AONC|Year-over-year earnings per one share growth for the last 12 months BGNE|CKPT: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months ELEV (Elevation Oncology Inc.)|ICAD: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Ikena Oncology|Year-over-year net earnings per share growth for the last 12 months NTBL|Quarterly EPS earnings growth Viracta|Year-over-year earnings per share growth for the last twelve months MorphoSys (MOR)|NAYA (NAYA Biosciences Inc) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth AAPGV (Ascentage Pharma Group Ltd)
